HTG at ASCO 2022
ASCO 2022, the major conference post-pandemic in which HTG participated, was a huge success! The power of HTG technology was showcased by scientist from across the globe at the American Society of Clinical Oncology(ASCO) 2022 Annual Meeting, held at the McCormick Place in Chicago, Illinois on June 3-7. The most exciting discussions were around recent advances using ultra-efficient gene expression profiling (GEP) and sharing details on just how integral biomarker discovery is to modern oncology therapy. Highlights from the meeting including groundbreaking abstracts detailing use of the recently launched HTG Transcriptome Panel (HTP) are shared here.
Abstracts were presented by HTG’s key biopharma customers and scientific collaborators from both the United States and Europe highlighting the unique features, benefits and results utilizing HTG’s proprietary HTG EdgeSeq gene expression profiling (GEP) technology. Prominent among the research presented was the HTG Transcriptome Panel (HTP). The HTP, released for commercial use in August 2021, enables the capture of comprehensive and reliable human transcriptome data using a fraction of the sample typically required by other GEP methods.
Genmab US, Inc. from Plainsboro, NJ presented a poster and an abstract titled “DLBCL cell of origin typing and whole transcriptome analysis using single slides with HTG EdgeSeq” in which they highlighted how our technology helped them evaluate the whole transcriptome from a single slide, preserving patient tissue, and how their finding may yield insights into tumor evolution and therapeutic mechanisms of action across the DLBCL treatment landscape.
Institute of Pathology, Philipps-University Marburg and University Hospital Marburg, from Marburg, Germany presented another poster and an abstract titled “Biomarkers for response to immunotherapy in triple-negative breast cancer: Differences between survival and pCR biomarkers”.Here, with the help of our technology, the researchers found that breast cancer patients’ biomarkers for immune response are linked to improved survival with pCR biomarkers.
Group of Advanced Therapies and Biomarkers in Sarcomas, Health Research Institute-Fundación Jiménez Díaz University Hospital, from Madrid, Spain presented yet another poster and an abstract titled “Prognostic value of EZH2 expression for immunotherapy-based schemes in advanced soft-tissue sarcoma: A translational research from Spanish Group of Research on Sarcoma (GEIS)”. Here the researchers used our HTG EdgeSeq OBP highlight that low expression of EZH2 was associated with better outcome in advanced STS patients treated with immunotherapy- based schemes.
HTG looks forward to exhibiting at future conferences and tradeshows. It is thrilling to see that HTG technology is making a positive difference around the globe.